Docosahexaenoic acid, protectins and dry eye

Area of Science:

• Ophthalmology
• Nutritional Science
• Inflammation Research

Background:

• Dry eye syndrome (DES) is a prevalent condition affecting millions globally.
• Current treatments for DES offer limited efficacy for some patients.
• Omega-3 polyunsaturated fatty acids (PUFAs) are being investigated for their therapeutic potential in DES.

Purpose of the Study:

• To review recent data on the role of omega-3 fatty acids, specifically docosahexaenoic acid (DHA) and its derivatives, in managing dry eye syndrome.
• To evaluate the efficacy of DHA and its metabolites as a potential treatment for DES.

Main Methods:

• Review of current scientific literature on omega-3 fatty acids and dry eye syndrome.
• Analysis of studies investigating the anti-inflammatory and regenerative properties of DHA derivatives.
• Examination of preclinical (animal models) and preliminary clinical data.

Main Results:

• Dietary supplementation with PUFAs, including alpha-linolenic acid, shows potential in improving DES signs and symptoms.
• DHA derivatives, such as resolvin E1 (RvE1) and neuroprotectin D1, are key mediators of DHA's anti-inflammatory effects in DES.
• Topical RvE1 reduced inflammation in a mouse model of dry eye.
• Combination therapy with DHA and pigment epithelium-derived factor accelerated corneal nerve regeneration and reduced DES signs in animal studies.

Conclusions:

• While optimal dietary supplementation strategies require further research, DHA and its derivatives show promise as a safe and effective topical treatment for DES.
• The therapeutic benefits of DHA in DES may stem from its anti-inflammatory actions and its role in regenerating damaged corneal nerves.